NDATOPICALLOTION
Approved
Feb 1977
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
19
Data completeness
4/8 — Partial
DIPROSONE (betamethasone dipropionate) by Merck & Co. is [see ] . Approved for psoriasis, atopic dermatitis. First approved in 1977.
Drug data last refreshed Yesterday · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DIPROSONE (betamethasone dipropionate) is a potent topical corticosteroid approved in 1977 for psoriasis and atopic dermatitis. It works through cellular signaling and immune modulation to reduce inflammation, though its precise mechanism in dermatologic conditions remains incompletely defined. The lotion formulation enables broad skin coverage for inflammatory skin diseases.
LOE Approaching
Product approaching loss of exclusivity with diminished commercial priority; expect smaller dedicated brand teams and shift toward generic stewardship or SKU rationalization.
Mechanism of Action
[see ] . Betamethasone dipropionate is a corticosteroid. Corticosteroids play a role in cellular signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action for the treatment of tinea pedis, tinea cruris and tinea corporis is unknown.
Indications (2)
Worked on DIPROSONE at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.